Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

ABSTRACT:

Context

Drug therapy for adrenocortical carcinoma (ACC), a rare and lethal malignancy, is largely empirical and ineffective. New treatments directed at molecular targets critical to the pathophysiology of ACC may prove more efficacious.

Objective

The objective of the study was to profile human adrenal tumors and ACC cell lines to assess activated IGF signaling and determine the efficacy of two IGF receptor (IGF-1R) antagonists alone and in combination with mitotane.

Experimental design

ACC cell lines that display or lack activated IGF signaling are used to assess the effects of two IGF-1R antagonists in cultured cells and ACC xenograft tumors.

Results

Transcriptional profiling data derived from DNA microarray analysis of human adrenal tumors implicate IGF2 as t

SUBMITTER: Barlaskar FM 

PROVIDER: S-EPMC2630877 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature